Since its inception in 1995, the University of Michigan Comprehensive Cancer Center (UMCCC) Prostate Cancer SPORE has endeavored to tap the vast intellectual and physical resources of the University of Michigan community to decrease the morbidity and mortality of prostate cancer. The SPORE supports an interactive group of basic and clinical investigators in a translational research program that has made major discoveries in developing new interventions in the diagnosis, prevention, and treatment of prostate cancer. The success of the translational mission of the SPORE was exemplified this year by our integrated team of investigators working together and utilizing SPORE resources to win the 1st annual AACR Team Science Award for the discovery of the importance of the TMPRSS:ETS family gene fusions in prostate cancer tumorigenesis. This Award was established by the American Association for Cancer Research (AACR) to acknowledge and catalyze the growing importance of interdisciplinary teams to the understanding of cancer and/or the translation of research discoveries into clinical cancer applications. This competing renewal application consists of four multidisciplinary research projects: Project 1: Molecular Sub-typing of Prostate Cancer Based on Recurrent Gene Fusions. Project 2: Small-molecule approach to reactivate p53 activity as a new therapeutic strategy for the treatment of advanced human prostate cancer. Project 3: Defining Genetic Risk Factors for Brothers of Men with Prostate Cancer. Project 4: Systemic inhibition of monocyte chemoattractant protein -1 (MCP-1;CCL2) for the treatment of prostate cancer. These projects are complemented by ongoing successful Career Development and Research Development Programs. The projects and programs are supported by a strong ongoing institutional commitment of money and space as well as three cores: Administration Core, Biostatistics Core, and the Tissue Core. This Prostate SPORE program continues to place premiums on rigorous scientific reviewing of its translational research programs, pairing of basic and clinical investigators, drawing on the expertise of scientists outside the field of prostate cancer, and utilizing flexibility to fund promising new research approaches. The interaction of our multidisciplinary group of investigators clearly makes the Prostate SPORE program at the University of Michigan Comprehensive Cancer Center greater than the sum of its individual parts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA069568-15
Application #
8281667
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Program Officer
Hruszkewycz, Andrew M
Project Start
1997-08-01
Project End
2014-05-31
Budget Start
2012-06-01
Budget End
2014-05-31
Support Year
15
Fiscal Year
2012
Total Cost
$2,300,000
Indirect Cost
$828,720
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Rye, Morten Beck; Bertilsson, Helena; Andersen, Maria K et al. (2018) Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized. BMC Cancer 18:478
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Singhal, Udit; Wang, Yugang; Henderson, James et al. (2018) Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res 16:643-654
Wang, Xiaoju; Qiao, Yuanyuan; Asangani, Irfan A et al. (2017) Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer Cell 31:532-548.e7
Blattner, Mirjam; Liu, Deli; Robinson, Brian D et al. (2017) SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell 31:436-451
Dai, Xiangpeng; Gan, Wenjian; Li, Xiaoning et al. (2017) Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med 23:1063-1071
Lin, Ke-Chih; Torga, Gonzalo; Wu, Amy et al. (2017) Epithelial and mesenchymal prostate cancer cell population dynamics on a complex drug landscape. Converg Sci Phys Oncol 3:
Piert, Morand; Montgomery, Jeffrey; Kunju, Lakshmi Priya et al. (2016) 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies. J Nucl Med 57:1065-70
Van Allen, Eliezer M; Robinson, Dan; Morrissey, Colm et al. (2016) A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. Oncotarget 7:52888-52899
Mehra, Rohit; Udager, Aaron M; Ahearn, Thomas U et al. (2016) Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. Eur Urol 70:549-552

Showing the most recent 10 out of 527 publications